Promising
Vilon (Lys-Glu)
The prediction game
Call it: rising or fading?
Where does Vilon (Lys-Glu) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.4/10
Vilon sits in caution because it pairs a coherent, single-source mechanism with an almost empty human outcomes file and zero independent confirmation. If you are a curious experimenter who already accepts you are running an unreplicated peptide, who wants a low-risk curiosity rather than a proven tool, and who can verify material as best you can, it is a low-drama experiment that is probably harmless. If you expect evidence-backed immune or anti-aging benefit, the data is not there, and the smarter move is a better-evidenced Khavinson peptide like Epitalon or Thymalin. The two things to keep front of mind are the total absence of independent replication and the dose mismatch between the microgram studies and the higher grey-market protocols. ✅ Best for: Curious experimenters who understand they are running a single-source, unreplicated peptide and want a curiosity rather than a proven tool. People drawn to the immune and geroprotective story who will judge it honestly on their own response over a short course. Anyone who can verify identity and sterility of grey-market material as best they can. Users who already have the immune and longevity basics dialed in and want a low-stakes add-on they are not counting on. ❌ Avoid if: You have active or suspected cancer, since immune and neuroendocrine experimentation is unwise there. You are pregnant or breastfeeding, with no human safety data. You expect proven results, because the evidence base is single-source, unreplicated, and untested in any registered trial. You cannot source or verify material, since identity, purity, and sterility of grey-market peptide are unknown. You would be better served by a better-evidenced sibling, in which case Epitalon or Thymalin is the smarter spend.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 6.4/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.